Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel diseases

Takanori Kanai, Mamoru Watanabe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

As our understanding of the immunological and genetic basis of inflammatory bowel disease (IBD) grows, potential therapeutic options are being developed at a rapid pace. Nevertheless, new drugs for IBD are needed because about half of all patients with severe ulcerative colitis (UC) eventually undergo colectomy, and a significant part of Crohn's disease (CD) patients do not respond to standard medical therapies, including immunosuppressants and TNF-α neutralising antibodies, or suffer from significant side effects. Finally, recurrence of disease activity following remission is frequent in both UC and CD, and there is an unmet need for effective maintenance strategies. It is well-known that immune responses in the intestine remain in a state of controlled inflammation, suggesting that not only does active suppression by regulatory T (TR) cells play an important role in the normal intestinal homeostasis, but also its dysregulation might lead to the development of IBD. TR cells are functional subsets of T cells that downregulate adaptive immune responses by interfering with the activation of dendritic cells and proliferation of T cells. From experimental work it is now clear that TR cells play a critical role in maintaining immune homeostasis, and several therapeutic approaches have been targeted at the induction of T R cells in order to control mucosal inflammation. Before using T R cells clinically as living immunosuppressants for the treatment of IBD, however, we have to pass many critical checkpoints, such as the in vitro expansion of TR cells and the confirmation of their safety. This paper will discuss recently gained knowledge of human TR cells and the possibility of their clinical usages as a new strategy for the treatment of IBD.

Original languageEnglish
Pages (from-to)451-462
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume5
Issue number4
DOIs
Publication statusPublished - 2005 Apr
Externally publishedYes

Fingerprint

T-cells
Regulatory T-Lymphocytes
Inflammatory Bowel Diseases
Immunosuppressive Agents
Ulcerative Colitis
Crohn Disease
Homeostasis
Therapeutics
Inflammation
Colectomy
T-Lymphocyte Subsets
Adaptive Immunity
Neutralizing Antibodies
Dendritic Cells
Intestines
Down-Regulation
Maintenance
Cell Proliferation
T-Lymphocytes
Safety

Keywords

  • CD4CD25 regulatory T cells
  • Cell transfusion therapy
  • Human
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel diseases. / Kanai, Takanori; Watanabe, Mamoru.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 4, 04.2005, p. 451-462.

Research output: Contribution to journalArticle

@article{904605ce749f46d6838f9f6512127584,
title = "Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel diseases",
abstract = "As our understanding of the immunological and genetic basis of inflammatory bowel disease (IBD) grows, potential therapeutic options are being developed at a rapid pace. Nevertheless, new drugs for IBD are needed because about half of all patients with severe ulcerative colitis (UC) eventually undergo colectomy, and a significant part of Crohn's disease (CD) patients do not respond to standard medical therapies, including immunosuppressants and TNF-α neutralising antibodies, or suffer from significant side effects. Finally, recurrence of disease activity following remission is frequent in both UC and CD, and there is an unmet need for effective maintenance strategies. It is well-known that immune responses in the intestine remain in a state of controlled inflammation, suggesting that not only does active suppression by regulatory T (TR) cells play an important role in the normal intestinal homeostasis, but also its dysregulation might lead to the development of IBD. TR cells are functional subsets of T cells that downregulate adaptive immune responses by interfering with the activation of dendritic cells and proliferation of T cells. From experimental work it is now clear that TR cells play a critical role in maintaining immune homeostasis, and several therapeutic approaches have been targeted at the induction of T R cells in order to control mucosal inflammation. Before using T R cells clinically as living immunosuppressants for the treatment of IBD, however, we have to pass many critical checkpoints, such as the in vitro expansion of TR cells and the confirmation of their safety. This paper will discuss recently gained knowledge of human TR cells and the possibility of their clinical usages as a new strategy for the treatment of IBD.",
keywords = "CD4CD25 regulatory T cells, Cell transfusion therapy, Human, Inflammatory bowel disease",
author = "Takanori Kanai and Mamoru Watanabe",
year = "2005",
month = "4",
doi = "10.1517/14712598.5.4.451",
language = "English",
volume = "5",
pages = "451--462",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel diseases

AU - Kanai, Takanori

AU - Watanabe, Mamoru

PY - 2005/4

Y1 - 2005/4

N2 - As our understanding of the immunological and genetic basis of inflammatory bowel disease (IBD) grows, potential therapeutic options are being developed at a rapid pace. Nevertheless, new drugs for IBD are needed because about half of all patients with severe ulcerative colitis (UC) eventually undergo colectomy, and a significant part of Crohn's disease (CD) patients do not respond to standard medical therapies, including immunosuppressants and TNF-α neutralising antibodies, or suffer from significant side effects. Finally, recurrence of disease activity following remission is frequent in both UC and CD, and there is an unmet need for effective maintenance strategies. It is well-known that immune responses in the intestine remain in a state of controlled inflammation, suggesting that not only does active suppression by regulatory T (TR) cells play an important role in the normal intestinal homeostasis, but also its dysregulation might lead to the development of IBD. TR cells are functional subsets of T cells that downregulate adaptive immune responses by interfering with the activation of dendritic cells and proliferation of T cells. From experimental work it is now clear that TR cells play a critical role in maintaining immune homeostasis, and several therapeutic approaches have been targeted at the induction of T R cells in order to control mucosal inflammation. Before using T R cells clinically as living immunosuppressants for the treatment of IBD, however, we have to pass many critical checkpoints, such as the in vitro expansion of TR cells and the confirmation of their safety. This paper will discuss recently gained knowledge of human TR cells and the possibility of their clinical usages as a new strategy for the treatment of IBD.

AB - As our understanding of the immunological and genetic basis of inflammatory bowel disease (IBD) grows, potential therapeutic options are being developed at a rapid pace. Nevertheless, new drugs for IBD are needed because about half of all patients with severe ulcerative colitis (UC) eventually undergo colectomy, and a significant part of Crohn's disease (CD) patients do not respond to standard medical therapies, including immunosuppressants and TNF-α neutralising antibodies, or suffer from significant side effects. Finally, recurrence of disease activity following remission is frequent in both UC and CD, and there is an unmet need for effective maintenance strategies. It is well-known that immune responses in the intestine remain in a state of controlled inflammation, suggesting that not only does active suppression by regulatory T (TR) cells play an important role in the normal intestinal homeostasis, but also its dysregulation might lead to the development of IBD. TR cells are functional subsets of T cells that downregulate adaptive immune responses by interfering with the activation of dendritic cells and proliferation of T cells. From experimental work it is now clear that TR cells play a critical role in maintaining immune homeostasis, and several therapeutic approaches have been targeted at the induction of T R cells in order to control mucosal inflammation. Before using T R cells clinically as living immunosuppressants for the treatment of IBD, however, we have to pass many critical checkpoints, such as the in vitro expansion of TR cells and the confirmation of their safety. This paper will discuss recently gained knowledge of human TR cells and the possibility of their clinical usages as a new strategy for the treatment of IBD.

KW - CD4CD25 regulatory T cells

KW - Cell transfusion therapy

KW - Human

KW - Inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=17844376787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844376787&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.4.451

DO - 10.1517/14712598.5.4.451

M3 - Article

C2 - 15934825

AN - SCOPUS:17844376787

VL - 5

SP - 451

EP - 462

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -